TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11576977

Group type: EXPERIMENTAL
Intervention: Specialist nurse intervention
Number of subjects: 165

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 165
Study: 8418403

Group type: EXPERIMENTAL
Intervention: Nucleus multichannel implant (implant 2)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ineraid multichannel implant (implant 1)
Number of subjects: 82

Group type: COMPARATOR
Intervention: 3M/Vienna single‐channel implant (implant 3)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Nucleus multichannel implant (implant 2) with improved speech processor
Number of subjects: 82
Study: 3769719

Group type: EXPERIMENTAL
Intervention: Group management program
Number of subjects: 32

Group type: COMPARATOR
Intervention: Advice-educational technique
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combined groups (both interventions)
Number of subjects: 32
Study: 29779044

Group type: EXPERIMENTAL
Intervention: Posterolateral internal sphincterotomy (PLIS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy (LIS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PLIS
Number of subjects: 80

Group type: COMPARATOR
Intervention: LIS
Number of subjects: 80
Study: 27031685

Group type: EXPERIMENTAL
Intervention: Mepilex® dressing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Allevyn dressing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aquacel™ dressing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no dressing)
Number of subjects: 10
Study: 24859589

Group type: EXPERIMENTAL
Intervention: Spinal fusion (surgery)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 464
Study: 23727415

Group type: EXPERIMENTAL
Intervention: mirabegron 50 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: mirabegron 100 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 200
Study: 19716267

Group type: EXPERIMENTAL
Intervention: Nonrandomized comparative studies (NRCSs) of laparoscopic resection for colorectal cancer
Number of subjects: 8950

Group type: COMPARATOR
Intervention: Randomized controlled trials (RCTs) of laparoscopic resection for colorectal cancer
Number of subjects: 8950
Study: 17938146

Group type: EXPERIMENTAL
Intervention: Mother-infant or toddler parenting program (n = 65)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Enhanced waitlist group (n = 53)
Number of subjects: 118
Study: 16984640

Group type: EXPERIMENTAL
Intervention: Fascial interposition (FI) during vas occlusion by ligation and excision
Number of subjects: 1215

Group type: EXPERIMENTAL
Intervention: Ligation and excision without FI
Number of subjects: 1215

Group type: COMPARATOR
Intervention: Thermal cautery without FI
Number of subjects: 1215

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1215
Study: 14504948

Group type: EXPERIMENTAL
Intervention: Endurance exercise-trained subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untrained subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sinusoidal exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endurance exercise-trained and untrained subjects
Number of subjects: 0
Study: 10731455

Group type: EXPERIMENTAL
Intervention: Stair-climbing group (N = 12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (N = 10)
Number of subjects: 22
Study: 8958000

Group type: COMPARATOR
Intervention: Conventional formula lacking LCP (n=16)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 22:6n-3- and 20:4n-6-enriched formula (n=15)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Mother's breast milk (n=12)
Number of subjects: 43
Study: 1432827

Group type: EXPERIMENTAL
Intervention: Breast stimulation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: No method employed (Control)
Number of subjects: 60
Study: 2872950

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pancuronium-metocurine mixture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 40
Study: 31526207

Group type: EXPERIMENTAL
Intervention: Ketamine (0.25, 0.5, 1 mg/kg) administered at weekly intervals
Number of subjects: 12

Group type: COMPARATOR
Intervention: Midazolam (0.01 mg/kg)
Number of subjects: 12
Study: 29352421

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 3913

Group type: COMPARATOR
Intervention: Diabetes support and education
Number of subjects: 3913

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 3913
Study: 27831984

Group type: EXPERIMENTAL
Intervention: Baseline Patient-Reported Outcomes (PROs) including ODI, Scoliosis Research Society-23, Short Form-12
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Subset analysis of high-symptom patients (ODI ≥ 40)
Number of subjects: 286
Study: 25337988

Group type: EXPERIMENTAL
Intervention: Web-based intervention for health care professionals
Number of subjects: 69
Study: 23411526

Group type: EXPERIMENTAL
Intervention: Er:YAG laser preparation
Number of subjects: 53

Group type: COMPARATOR
Intervention: Mechanical preparation
Number of subjects: 53
Study: 20890176

Group type: EXPERIMENTAL
Intervention: Thrombolysis (100 mg of alteplase: 10 mg bolus followed by 90 mg intravenous infusion over 2 hours)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Thrombolysis (100 mg of alteplase)
Number of subjects: 72
Study: 19458433

Group type: EXPERIMENTAL
Intervention: TBI participants
Number of subjects: 7

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 7
Study: 16684811

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15205959

Group type: EXPERIMENTAL
Intervention: Aluminium and stainless steel blocks at surface temperatures of -2 degrees C and -10 degrees C, with contact forces of 1.0 N and 9.8 N.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Slow cooling conditions (>45 s to reach T(C)=1 degrees C) with index finger volume as a measure of hand size.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fast cooling conditions (<25 s to reach T(C)=1 degrees C).
Number of subjects: 14
Study: 11166484

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural intervention (CBT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 53
Study: 9292807

Group type: EXPERIMENTAL
Intervention: Holmium YAG laser
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional cutting tools
Number of subjects: 70
Study: 8161937

Group type: EXPERIMENTAL
Intervention: Low-grade non-Hodgkin's lymphoma (LG-NHL)
Number of subjects: 496
Study: 3536261

Group type: EXPERIMENTAL
Intervention: 1000 mg methylprednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 250 mg methylprednisolone
Number of subjects: 0
Study: 30146282

Group type: EXPERIMENTAL
Intervention: 125 g/d of regular cheese for 2 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Habitual diet for 2 weeks
Number of subjects: 17
Study: 27632557

Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Rupatadine 40 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Rupatadine (all doses)
Number of subjects: 27
Study: 24920841

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 41
Study: 22421169

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1005
Study: 20546674

Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells (BMMC) injected into the left ventricular free wall (9.6 ± 2.6 × 10(7) BMMC divided into 10 points)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: BMMC injection into the left ventricular free wall
Number of subjects: 15
Study: 18937123

Group type: EXPERIMENTAL
Intervention: Male partner with experience of extradyadic sexual activity (ESA)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Female partner with experience of extradyadic sexual activity (ESA)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Male partner of a woman with experience of ESA
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Attitude of male partner
Number of subjects: 399
Study: 16395998

Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference treatment
Number of subjects: 0
Study: 12211216

Group type: EXPERIMENTAL
Intervention: Galantamine 4 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Galantamine 8 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Galantamine (4 mg and 8 mg)
Number of subjects: 25
Study: 10599957

Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrates (PC) transfused immediately after cardiopulmonary bypass
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no PC)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrates (PC)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrates (PC) stored for 1 day
Number of subjects: 35
Study: 8831364

Group type: EXPERIMENTAL
Intervention: Verapamil (0.15 mg/kg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Propranolol (0.1 mg/kg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Procainamide (15 mg/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control state (no intervention)
Number of subjects: 34
Study: 2008800

Group type: EXPERIMENTAL
Intervention: Vaccination with a highly purified, inactivated virus particle vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naturally acquired tick‐borne encephalitis (TBE)
Number of subjects: 0
Study: 7117279

Group type: EXPERIMENTAL
Intervention: Cholescintigraphy
Number of subjects: 77
Study: 31535498

Group type: EXPERIMENTAL
Intervention: Early Active Mobilization (EAM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Immobilization
Number of subjects: 50
Study: 28930058

Group type: EXPERIMENTAL
Intervention: eCHECKUP TO GO intervention
Number of subjects: 221

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 221
Study: 26088378

Group type: EXPERIMENTAL
Intervention: Ivabradine 10 mg or 15 mg
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study: 24759957

Group type: EXPERIMENTAL
Intervention: Intensive treatment plus a theory‐based behaviour change intervention led by a facilitator
Number of subjects: 478

Group type: COMPARATOR
Intervention: Intensive treatment
Number of subjects: 478
Study: 22689805

Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m² per day as a 1-hour intravenous infusion for five consecutive days every 4 weeks
Number of subjects: 485

Group type: COMPARATOR
Intervention: Treatment choice (TC) - supportive care or cytarabine 20 mg/m² per day as a subcutaneous injection for 10 consecutive days every 4 weeks
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 485

Group type: COMPARATOR
Intervention: Treatment choice (TC)
Number of subjects: 485
Study: 19424073

Group type: EXPERIMENTAL
Intervention: Gabapentin (1.2 g oral, single dose 1 hour before surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 60
Study: 16697113

Group type: EXPERIMENTAL
Intervention: Physical therapy regimen including active exercises (10 appointments within 14 days)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard treatment (immobilization with a soft collar for 7 days)
Number of subjects: 200
Study: 15265256

Group type: EXPERIMENTAL
Intervention: Abacavir (ABC) 300 mg plus fixed-dose lamivudine 150 mg/zidovudine 300 mg (COM) twice daily
Number of subjects: 329

Group type: COMPARATOR
Intervention: Indinavir (IDV) plus COM twice daily
Number of subjects: 329
Study: 11413106

Group type: EXPERIMENTAL
Intervention: BIM26226
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 9160758

Group type: EXPERIMENTAL
Intervention: Verapamil SR (180 mg)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Trandolapril (1 mg)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Verapamil SR + Trandolapril (fixed combination)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 7961013

Group type: EXPERIMENTAL
Intervention: Multileaf collimator combined with three-dimensional treatment planning
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Conformal neutron beam delivery techniques
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control treatment with photons
Number of subjects: 245
Study: 3230458

Group type: EXPERIMENTAL
Intervention: HRA with feedback
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: HRA without feedback
Number of subjects: 350
Study: 31735430

Group type: EXPERIMENTAL
Intervention: Women with prior preeclampsia
Number of subjects: 275930

Group type: COMPARATOR
Intervention: Men
Number of subjects: 275930

Group type: EXPERIMENTAL
Intervention: Women with preeclampsia requiring preterm delivery
Number of subjects: 275930

Group type: COMPARATOR
Intervention: Women without prior preeclampsia
Number of subjects: 275930
Study: 29721715

Group type: EXPERIMENTAL
Intervention: Locoregional treatment (LRT)
Number of subjects: 21200

Group type: COMPARATOR
Intervention: No locoregional treatment (no-LRT)
Number of subjects: 21200

Group type: EXPERIMENTAL
Intervention: LRT (group 1, 0-7 points)
Number of subjects: 21200

Group type: EXPERIMENTAL
Intervention: LRT (group 2, 7-17 points)
Number of subjects: 21200

Group type: EXPERIMENTAL
Intervention: LRT (training cohort)
Number of subjects: 21200

Group type: EXPERIMENTAL
Intervention: LRT (internal validation)
Number of subjects: 21200
Study: 28186569

Group type: EXPERIMENTAL
Intervention: Depression (BDI score ≥14)
Number of subjects: 3086

Group type: EXPERIMENTAL
Intervention: Moderate depression (BDI score ≥20)
Number of subjects: 3086
Study: 26437532

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Doxycycline or Chloramphenicol (Control)
Number of subjects: 57
Study: 23782624

Group type: EXPERIMENTAL
Intervention: Nurse case management
Number of subjects: 275

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 275
Study: 20497261

Group type: EXPERIMENTAL
Intervention: David's classification (DC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Computer-assisted method (CASA SC)
Number of subjects: 120
Study: 18499556

Group type: COMPARATOR
Intervention: Iscador therapy (mistletoe preparation)
Number of subjects: 284
Study: 14691193

Group type: EXPERIMENTAL
Intervention: Conventional Automated Perimetry (CAP) with mental workload (PASAT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Luminance Size Threshold Perimetry (LSTP) with mental workload (PASAT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Paced Auditory Serial Addition Test (PASAT)
Number of subjects: 10
Study: 11605151

Group type: EXPERIMENTAL
Intervention: Low compliance dilation device (LCDD, polyethylene balloon, Rigiflex, Microvasive Boston Scientific, USA, n = 18)
Number of subjects: 35

Group type: COMPARATOR
Intervention: High compliance dilation device (HCDD, latex balloon, Rüsch Inc., Germany, n = 17)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups (LCDD and HCDD)
Number of subjects: 35
Study: 9717015

Group type: EXPERIMENTAL
Intervention: Low-dose sotalol (selective approach)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Non-selective approach (all patients treated)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Selective approach
Number of subjects: 214
Study: 7981992

Group type: EXPERIMENTAL
Intervention: SASP + MTX
Number of subjects: 40

Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 40
Study: 2921096

Group type: EXPERIMENTAL
Intervention: 0.2 mg Ro 16-6028
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.05 mg Ro 16-6028
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.1 mg Ro 16-6028
Number of subjects: 10
Study: 1168170

Group type: EXPERIMENTAL
Intervention: Live, attenuated recombinant influenza vaccine (Alice strain) administered intranasally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous, inactivated, bivalent influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 0
Study: 31677046

Group type: EXPERIMENTAL
Intervention: Monthly lifestyle education program including advice on nutritional changes and physical activity enhancement.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention-control group receiving monthly lectures on non-cardiovascular topics with verbal advice on healthy diet and exercise.
Number of subjects: 0
Study: 31256021

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 658
Study: 28287021

Group type: EXPERIMENTAL
Intervention: Static stretching intervention for 6 months
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Static stretching intervention for 3 months
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Detraining after 6 months
Number of subjects: 22
Study: 25982601

Group type: EXPERIMENTAL
Intervention: Dorzolamide, three times daily for three weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo, three times daily for three weeks
Number of subjects: 69
Study: 23952999

Group type: EXPERIMENTAL
Intervention: ivabradine (15 mg/day for 50% of patients, 10 mg/day for 28%)
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 1226
Study: 20948195

Group type: EXPERIMENTAL
Intervention: Intratympanic (IT) methylprednisolone injection
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ear drops of methylprednisolone
Number of subjects: 65

Group type: COMPARATOR
Intervention: Blank control (no treatment)
Number of subjects: 65
Study: 19637947

Group type: EXPERIMENTAL
Intervention: Fosamprenavir 1400 mg once/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Atazanavir 400 mg once/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fosamprenavir 1400 mg plus Atazanavir 400 mg once/day
Number of subjects: 21
Study: 16293317

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (45/6.4 mg/kg/day in two divided doses for 10 days)
Number of subjects: 180
Study: 15156472

Group type: EXPERIMENTAL
Intervention: Echinacea purpurea, 2.5 mL 3 times per day for 7 days before and 7 days after inoculation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo, 2.5 mL 3 times per day for 7 days before and 7 days after inoculation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Echinacea purpurea
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 11288041

Group type: EXPERIMENTAL
Intervention: Alcohol (0.4 g/kg body weight)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 8
Study: 9594206

Group type: EXPERIMENTAL
Intervention: Cuprophan (CU) membrane
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA) membrane
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Polysulphone (PS) membrane
Number of subjects: 22
Study: 8323333

Group type: EXPERIMENTAL
Intervention: subcutaneous human recombinant erythropoietin (r‐HuEpo)
Number of subjects: 11
Study: 3090274

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 91

Group type: COMPARATOR
Intervention: Combination of pethidine and hyoscine butyl bromide
Number of subjects: 91
Study: 29523267

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinic blood pressure (CBP) readings
Number of subjects: 0
Study: 27584019

Group type: EXPERIMENTAL
Intervention: Higher protein low fat diet (35% protein, 40% carbohydrate, 25% fat; n = 57)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Higher carbohydrate low fat diet (17% protein, 58% carbohydrate, 25% fat; n = 61)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 118
Study: 25033346

Group type: COMPARATOR
Intervention: Subepithelial connective tissue grafts (SCTG)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) allografts
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both groups (SCTG and ADM)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM)
Number of subjects: 13
Study: 22420717

Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 60

Group type: COMPARATOR
Intervention: LMA ProSeal
Number of subjects: 60
Study: 20042440

Group type: EXPERIMENTAL
Intervention: Gentler words for administration of the local anesthetic
Number of subjects: 140

Group type: COMPARATOR
Intervention: Harsher nocebo words for administration of the local anesthetic
Number of subjects: 140
Study: 18378354

Group type: EXPERIMENTAL
Intervention: Terbinafine (5‐8 mg/kg)
Number of subjects: 1286

Group type: COMPARATOR
Intervention: Griseofulvin (10‐20 mg/kg)
Number of subjects: 1286

Group type: EXPERIMENTAL
Intervention: Terbinafine (5‐8 mg/kg) in trial 1
Number of subjects: 1286

Group type: COMPARATOR
Intervention: Griseofulvin (10‐20 mg/kg) in trial 1
Number of subjects: 1286

Group type: EXPERIMENTAL
Intervention: Terbinafine (5‐8 mg/kg) in trial 2
Number of subjects: 1286

Group type: COMPARATOR
Intervention: Griseofulvin (10‐20 mg/kg) in trial 2
Number of subjects: 1286

Group type: EXPERIMENTAL
Intervention: Terbinafine (5‐8 mg/kg) for T. tonsurans
Number of subjects: 1286

Group type: COMPARATOR
Intervention: Griseofulvin (10‐20 mg/kg) for M. canis
Number of subjects: 1286
Study: 15800520

Group type: EXPERIMENTAL
Intervention: Patellar tendon (PT) autograft
Number of subjects: 85

Group type: COMPARATOR
Intervention: Semitendinosus and gracilis tendon (STG) autograft
Number of subjects: 85
Study: 12045062

Group type: EXPERIMENTAL
Intervention: Silicone-hydrogel balafilcon A (PureVision) worn on a 30-day continuous wear schedule
Number of subjects: 212

Group type: COMPARATOR
Intervention: Traditional hydrogel (Acuvue) worn on a 7-day extended wear schedule
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Both lens types
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Silicone-hydrogel balafilcon A (PureVision)
Number of subjects: 212